期刊
ONCOLOGIST
卷 26, 期 4, 页码 288-+出版社
WILEY
DOI: 10.1002/onco.13712
关键词
Avelumab; Radiotherapy; Abscopal effect; Multiple myeloma
类别
资金
- National Institutes of Health, Intramural Research Program
- Merck KGaA, Darmstadt, Germany
The combination of avelumab and radiotherapy for patients with relapsed/refractory multiple myeloma and extramedullary disease showed limited systemic clinical benefit, although patients still benefited from local radiotherapy. The combination was well tolerated compared to historical treatment regimens for relapsed/refractory multiple myeloma.
Background. Extramedullary disease (EMD) is recognized as an aggressive subentity of multiple myeloma (MM) with a need for novel therapeutic approaches. We therefore designed a proof-of-principle pilot study to evaluate the synergy between the combination of the anti-PD-L1, avelumab, and concomitant hypofractionated radiotherapy. Methods. This was a single-arm phase II Simon two-stage single center study that was prematurely terminated because of the COVID-19 pandemic after enrolling four patients. Key eligibility included patients with relapsed/refractory multiple myeloma (RRMM) who had exhausted or were not candidates for standard therapy and had at least one lesion amenable to radiotherapy. Patients received avelumab until progression or intolerable toxicity and hypofractionated radiotherapy to a focal lesion in cycle 2. Radiotherapy was delayed until cycle 2 to allow the avelumab to reach a study state, given the important observation from previous studies that concomitant therapy is needed for the abscopal effect. Results. At a median potential follow-up of 10.5 months, there were no objective responses, one minimal response, and two stable disease as best response. The median progression-free survival (PFS) was 5.3 months (95% confidence interval [CI]: 2.5-7.1 months), and no deaths occurred. There were no grade >= 3 and five grade 1-2 treatment-related adverse events. Conclusion. Avelumab in combination with radiotherapy for patients with RRMM and EMD was associated with very modest systemic clinical benefit; however, patients did benefit as usual from local radiotherapy. Furthermore, the combination was very well tolerated compared with historical RRMM treatment regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据